Vectura to buy SkyePharma for $621mm
Vectura Group PLC agreed to buy SkyePharma PLC for consideration of $621mm (£441mm). SkyePharma shareholders will receive 2.7977 new shares for each share held (£441.3mm valuation; 410.15p per share representing 7% premium over prior 10-day trading average). Alternatively shareholders can choose to receive partial consideration in cash. Annual pre-tax synergies are expected to be around £10mm, and will be fully realized by 2018.
- Medical Devices
- Topical Delivery
- Drug Delivery
- Acquisition of Private Biotech
- Full Acquisition
- Intra-Biotech Deal
- Payment Includes Cash
- Payment Includes Stock
Please contact Sales at: (212) 520-2765 or email [email protected]
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.